AKTS
Aktis Oncology, Inc. Common stockNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$903.13M
P/E Ratio
—
EPS
$-1.21
Beta
—
52W High
$29.16
52W Low
$14.72
50-Day MA
$19.00
200-Day MA
$19.29
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Aktis Oncology, Inc. Common stock
Akoustis Technologies, Inc., through its subsidiary, Akoustis, Inc., develops, designs, manufactures and sells radio frequency (RF) filter products for the wireless mobile device industry in the United States. The company is headquartered in Huntersville, North Carolina.
Fundamentals
| Revenue (TTM) | $6.50M |
| Gross Profit (TTM) | $-60.95M |
| EBITDA | $-72.36M |
| Operating Margin | -929.00% |
| Return on Equity | -29.40% |
| Return on Assets | -15.80% |
| Revenue/Share (TTM) | $7.99 |
| Book Value | $-159.68 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | 139.01 |
| EV/Revenue | 114.37 |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 100.40% |
| Shares Outstanding | $53.30M |
| Float | $24.88M |
| % Insiders | 12.28% |
| % Institutions | 40.97% |
Analyst Ratings
Consensus ($32.50 target)
1
Strong Buy3
BuyData last updated: 4/7/2026